Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 27Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 15Lymphoma 9Hodgkin Disease 9Neoplasms, Plasma Cell 5Myelodysplastic Syndromes 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 2Pancreatic Neoplasms 2Gliosarcoma 2Glioma 2Glioblastoma 2Warts 1Pinealoma 1Paraproteinemias 1Ovarian Neoplasms 1Neutropenia 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Lymphoproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1

Interventions

plerixafor 1ofatumumab 1Panzyga 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Agammaglobulinemia × plerixafor × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡